The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia - PubMed (original) (raw)
The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia
Benjamin J Thompson et al. J Exp Med. 2007.
Abstract
Recent studies have shown that activating mutations of NOTCH1 are responsible for the majority of T cell acute lymphoblastic leukemia (T-ALL) cases. Most of these mutations truncate its C-terminal domain, a region that is important for the NOTCH1 proteasome-mediated degradation. We report that the E3 ligase FBW7 targets NOTCH1 for ubiquitination and degradation. Our studies map in detail the amino acid degron sequence required for NOTCH1-FBW7 interaction. Furthermore, we identify inactivating FBW7 mutations in a large fraction of human T-ALL lines and primary leukemias. These mutations abrogate the binding of FBW7 not only to NOTCH1 but also to the two other characterized targets, c-Myc and cyclin E. The majority of the FBW7 mutations were present during relapse, and they were associated with NOTCH1 HD mutations. Interestingly, most of the T-ALL lines harboring FBW7 mutations were resistant to gamma-secretase inhibitor treatment and this resistance appeared to be related to the stabilization of the c-Myc protein. Our data suggest that FBW7 is a novel tumor suppressor in T cell leukemia, and implicate the loss of FBW7 function as a potential mechanism of drug resistance in T-ALL.
Figures
Figure 1.
Physical and functional association between FBW7 and NOTCH1. (A) Schematic depiction of the NOTCH1 (N1) protein domains, and N1-IC WT (N1-ICWT) and 82 and 162 ΔPEST mutants (N1-ICΔ82 and N1-ICΔ162). Asterisk denotes L1601P mutation. The FBW7 degron is highlighted in gray. LNR, LIN-Notch repeat domain; RAM, RBJ-κ–associated module; TAD, transcriptional activation domain; PEST, P-E-S-T–rich domain; HD, heterodimerization domain. (B and C) Coimmunoprecipitation experiments using anti-Flag beads or anti-HA beads, showing interaction between DN FBW7 and N1-ICWT, but DN FBW7 (D) does not interact with N1-ICΔ82 and N1-ICΔ162. (E) Cotransfection with FBW7α repressed N1L1601P (P < 0.02), but not N1L1601P-Δ82, in reporter assays using a CSL luciferase reporter. pCDNA3.1 represents the control, “empty” expression vector. Error bars represent the SD of duplicate wells.
Figure 2.
Mutational analysis of the FBW7 NOTCH1 degron. (A) Coimmunoprecipitation experiment using threonine mutants of N1-IC (N1-ICT2133A, N1-ICT2467A, N1-ICT2484A, and N1-ICT2512A) and DN FBW7. Only N1-ICT2512A was unable to coimmunoprecipitate with DN FBW7. (B) Cell lysates from Bosc23 cells transfected with N1L1601P or N1L1601P-T2512A and FBW7α were used for luciferase reporter assays. N1L1601P-T2512A was not repressed by FBW7α. (C) Cell lysates from HeLa cells transfected with full-length N1 mutants were used for luciferase reporter assays. N1L1601P-Δ82 and N1L1601P-T2512A induced a 15- and 5-fold increase in transcriptional activity, respectively, compared with N1L1601P. (D) In vivo ubiquitination assay using Bosc23 cells transfected with N1-ICWT, N1-ICΔ82, or N1-ICT2512A with or without SCFFBW7α (SKP1, CUL1, ROC1, and FBW7α) and Ub-HA. SCFFBW7α enhanced polyubiquitination of N1-ICWT, but not of N1-ICΔ82 or N1-ICT2512A. (E) A negative charge is required at position 2516 (T+4). Interaction with DN FBW7 is partially preserved with N1-ICE2516D, but abolished with N1-ICE2516A. (F) Mutation of two CDK8 phosphorylation sites prevents N1-IC interaction with FBW7. A mutant lacking both S2514 and S2517 (N1-ICS2514A-S2517A) did not coimmunoprecipitate with DN FBW7. Error bars represent the SD of duplicate wells.
Figure 3.
FBW7 mutations in T-ALL preclude interaction with NOTCH1, c-Myc, and cyclin E. (A) Schematic depiction of the positions of the FBW7 binding pocket and DN FBW7. (B) Chromatograms showing mutations of FBW7 R465 and R505 found in CEM and P12-ICHIKAWA T-ALL cell lines. DND41 cells express WT FBW7. Arrows indicate mutated nucleotides. (C) Coimmunoprecipitation experiments demonstrating the inability of DN FBW7R465C, DN FBW7R479Q, and DN FBW7R505C to interact with N1-IC. (D and E) The same DN FBW7 mutants as in C do not interact with c-Myc and cyclin E. Asterisk in E indicates a nonspecific band.
Figure 4.
Restoration of FBW7 expression in CEM cells (FBW7MUT) suppresses NOTCH1 target genes. (A and B) Efficient restoration of FBW7WT in CEM T-ALL cells after transduction with a Flag-FBW7α–expressing retrovirus (MigR1-FBW7α). Cells were infected with empty MigR1 vector as a control. (A) RT-PCR amplified Flag-FBW7α only in cells infected with MigR1-FBW7α. (B) Immunofluorescence staining of FACS-sorted CEM cells infected with MigR1-FBW7α using FITC-conjugated anti-Flag antibody shows nuclear localization of the construct. (C) Real-time RT-PCR was used to quantify the expression of the NOTCH1 target genes, DELTEX1, and HES1 in CEM cells infected as in A Infection with MigR1-FBW7α suppressed the two genes (P < 0.0001 for both). Error bars represent the SD of triplicate wells.
Figure 5.
FBW7 mutations as a mechanism of resistance to γ-secretase inhibition. (A) T-ALL cell lines were treated with MG132 (20 μM for 6 h) and analyzed for expression of c-Myc and actin. Treatment with MG132 resulted in accumulation of c-Myc in KOPTK cells, which express WT FBW7, but not in Be13 and P12-ICHIKAWA cells, which express no and mutant FBW7, respectively. (B) Expression of N1-IC and c-Myc after treatment with Compound E (CompE) for 1–4 d. c-Myc expression declines only in KOPTK1 cells, which are sensitive to this treatment, but not in Be13 and P12-ICHIKAWA cells, which are resistant. N1-IC expression decreased in all of the cell lines, reflecting inhibition of γ-secretase–mediated cleavage of NOTCH1. Actin expression was used as a loading control for both A and B.
Similar articles
- FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors.
O'Neil J, Grim J, Strack P, Rao S, Tibbitts D, Winter C, Hardwick J, Welcker M, Meijerink JP, Pieters R, Draetta G, Sears R, Clurman BE, Look AT. O'Neil J, et al. J Exp Med. 2007 Aug 6;204(8):1813-24. doi: 10.1084/jem.20070876. Epub 2007 Jul 23. J Exp Med. 2007. PMID: 17646409 Free PMC article. - Fbw7 promotes ubiquitin-dependent degradation of c-Myb: involvement of GSK3-mediated phosphorylation of Thr-572 in mouse c-Myb.
Kitagawa K, Hiramatsu Y, Uchida C, Isobe T, Hattori T, Oda T, Shibata K, Nakamura S, Kikuchi A, Kitagawa M. Kitagawa K, et al. Oncogene. 2009 Jun 25;28(25):2393-405. doi: 10.1038/onc.2009.111. Epub 2009 May 4. Oncogene. 2009. PMID: 19421138 - New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.
Hales EC, Taub JW, Matherly LH. Hales EC, et al. Cell Signal. 2014 Jan;26(1):149-61. doi: 10.1016/j.cellsig.2013.09.021. Epub 2013 Oct 16. Cell Signal. 2014. PMID: 24140475 Review. - Notch1 contributes to mouse T-cell leukemia by directly inducing the expression of c-myc.
Sharma VM, Calvo JA, Draheim KM, Cunningham LA, Hermance N, Beverly L, Krishnamoorthy V, Bhasin M, Capobianco AJ, Kelliher MA. Sharma VM, et al. Mol Cell Biol. 2006 Nov;26(21):8022-31. doi: 10.1128/MCB.01091-06. Epub 2006 Sep 5. Mol Cell Biol. 2006. PMID: 16954387 Free PMC article. - Therapeutic targeting of NOTCH1 signaling in T-cell acute lymphoblastic leukemia.
Palomero T, Ferrando A. Palomero T, et al. Clin Lymphoma Myeloma. 2009;9 Suppl 3(Suppl 3):S205-10. doi: 10.3816/CLM.2009.s.013. Clin Lymphoma Myeloma. 2009. PMID: 19778842 Free PMC article. Review.
Cited by
- Molecular insights and clinical implications for the tumor suppressor role of SCFFBXW7 E3 ubiquitin ligase.
Qi Y, Rezaeian AH, Wang J, Huang D, Chen H, Inuzuka H, Wei W. Qi Y, et al. Biochim Biophys Acta Rev Cancer. 2024 Sep;1879(5):189140. doi: 10.1016/j.bbcan.2024.189140. Epub 2024 Jun 21. Biochim Biophys Acta Rev Cancer. 2024. PMID: 38909632 Review. - Notch signaling pathway in cancer: from mechanistic insights to targeted therapies.
Shi Q, Xue C, Zeng Y, Yuan X, Chu Q, Jiang S, Wang J, Zhang Y, Zhu D, Li L. Shi Q, et al. Signal Transduct Target Ther. 2024 May 27;9(1):128. doi: 10.1038/s41392-024-01828-x. Signal Transduct Target Ther. 2024. PMID: 38797752 Free PMC article. Review. - Protein neddylation and its role in health and diseases.
Zhang S, Yu Q, Li Z, Zhao Y, Sun Y. Zhang S, et al. Signal Transduct Target Ther. 2024 Apr 5;9(1):85. doi: 10.1038/s41392-024-01800-9. Signal Transduct Target Ther. 2024. PMID: 38575611 Free PMC article. Review. - Mechanism study of ubiquitination in T cell development and autoimmune disease.
Yu H, Yang W, Cao M, Lei Q, Yuan R, Xu H, Cui Y, Chen X, Su X, Zhuo H, Lin L. Yu H, et al. Front Immunol. 2024 Mar 18;15:1359933. doi: 10.3389/fimmu.2024.1359933. eCollection 2024. Front Immunol. 2024. PMID: 38562929 Free PMC article. Review. - NOTCH localizes to mitochondria through the TBC1D15-FIS1 interaction and is stabilized via blockade of E3 ligase and CDK8 recruitment to reprogram tumor-initiating cells.
Choi HY, Zhu Y, Zhao X, Mehta S, Hernandez JC, Lee JJ, Kou Y, Machida R, Giacca M, Del Sal G, Ray R, Eoh H, Tahara SM, Chen L, Tsukamoto H, Machida K. Choi HY, et al. Exp Mol Med. 2024 Feb;56(2):461-477. doi: 10.1038/s12276-024-01174-6. Epub 2024 Feb 27. Exp Mol Med. 2024. PMID: 38409448 Free PMC article.
References
- Grabher, C., H. von Boehmer, and A.T. Look. 2006. Notch 1 activation in the molecular pathogenesis of T-cell acute lymphoblastic leukaemia. Nat. Rev. Cancer. 6:1–13. - PubMed
- Artavanis-Tsakonas, S., M.D. Rand, and R.J. Lake. 1999. Notch signaling: cell fate control and signal integration in development. Science. 284:770–776. - PubMed
- Maillard, I., T. Fang, and W.S. Pear. 2005. Regulation of lymphoid development, differentiation, and function by the notch pathway. Annu. Rev. Immunol. 23:945–974. - PubMed
- Rothenberg, E.V., and T. Taghon. 2005. Molecular genetics of T cell development. Annu. Rev. Immunol. 23:601–649. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01 CA105129/CA/NCI NIH HHS/United States
- R01 CA120196-02/CA/NCI NIH HHS/United States
- CA120196/CA/NCI NIH HHS/United States
- R01 CA120196/CA/NCI NIH HHS/United States
- R01CA105129/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources